Table 1.
Family | Virus | Experimental evidence | Proposed domain(s) requireda | Proposed mechanism(s) of action | Reference(s) |
---|---|---|---|---|---|
Herpesviridae (dsDNA group) | HCMV | Overexpression of viperin, knockdown of viperin, co-IPs, microscopy | RS domain | Antiviral effects only if expressed prior to infection through an unknown mechanism; proviral: the HCMV vMIA protein binds to viperin and localizes it to the mitochondria where it binds to host proteins, altering cellular metabolism that favors HCMV replication; replacing the N terminus for a mitochondrial targeting signal is sufficient | 3, 22, 23 |
KSHV | Overexpression of viperin, knockdown of viperin, co-IP, pharmacological disruption of lipid droplets, in vitro oxidation assays | Controversial—authors proposed protein methionines are substrates for viperin despite published biochemical evidence to the contrary | Proviral: binds to and promotes methionine oxidation of the KSHV helicase ORF44, which in turn enhances its stability | 69 | |
Flaviviridae (+ssRNA group) | Hepatitis C virus | Overexpression of viperin, knockdown of viperin, replicons, FRET analysis, in vitro primer extension assays with purified RdRp | RS and aromatic amino acids on C terminus required when using replicon colony formation assays; C terminus required for binding to VAP-A and NS5A; role for the N terminus is controversial | Binds to NS5A through its C terminus and to the host factor VAP-A in replication complexes, which may interfere with viral replication; chain termination of RNA replication through ddhCTP-dependent inhibition of RdRp | 1, 20, 75, 78 |
West Nile virus | Overexpression of viperin, replicons, Viperin−/− mice, in vitro primer extension assays with purified RdRp | RS domain and N terminus (only partially) | Inhibition is seen in virus-like particles and subgenomic replicons; likely chain termination of RNA replication through ddhCTP-dependent inhibition of RdRp | 1, 76, 94 | |
Dengue virus type 2 | Overexpression of viperin, knockdown of viperin, replicons, FRET analysis, in vitro primer extension assays with purified RdRp | Controversial—RS domain required when using VLP; only C terminus required during infection | Inhibition is seen in VLPs, subgenomic replicons, and infections; interacts with capsid and NS3; likely chain termination of RNA replication through ddhCTP-dependent inhibition of RdRp | 1, 19, 76 | |
Zika virus | Overexpression of viperin, viperin knockout cells, microscopy, co-IPs, in vitro primer extension assays with purified RdRp, addition of exogenous ddhCTP to cells | C-terminal domain (especially the last four amino acids); N-terminal and RS domains are indispensable | Likely interferes with RNA replication; interacts with NS3 and promotes its degradation; chain termination of RNA replication through ddhCTP-dependent inhibition of RdRp | 1, 28, 77, 79, 95 | |
Tick-borne encephalitis virus | Overexpression of viperin, depletion of CIAO1, Fe55 incorporation, SAM depletion, flotation assays, microscopy, co-IPs | RS domain and incorporation of Fe are required; aromatic residues in C terminus are required for maturation of viperin and Fe incorporation | Inhibits viral +ssRNA synthesis through an RS-dependent mechanism; interacts with structural and nonstructural proteins and promotes degradation of NS3; induces release of noninfectious capsids and may prevent virion maturation by promoting Golgi-independent secretion of capsids | 29, 77, 82 | |
JEV | Overexpression of viperin in presence of proteasome inhibitor | ND | Viperin is normally degraded in JEV-infected cells; inhibition of the proteasome rescues the antiviral properties of viperin by an unknown mechanism | 56 | |
Langat virus | Flotation assays, microscopy, Viperin−/− mice | ND | Unknown; proposed to be through induction of secretion of noninfectious capsids; cell-type-specific effects in vivo | 82, 96 | |
Picornaviridae (+ssRNA group) | Human rhinovirus | Viperin knockdown | ND | Unknown; unlikely to be dependent on ddhCTP production | 1, 97 |
Enterovirus A71 | Overexpression of viperin, knockdown of viperin, co-IP | N-terminal domain | Binding to viral protein 2C at the ER through its N-terminal domain | 98 | |
Togaviridae (−ssRNA group) | Chikungunya virus | Overexpression of viperin, Viperin−/− mice, colocalization with nsP2 at the ER | N-terminal domain is sufficient; intact RS domain is required in full-length viperin | Unknown | 81 |
Sindbis virus | Viperin knockdown | ND | Unknown | 56, 99 | |
Rhabdoviridae (−ssRNA group) | Rabies virus | Overexpression of viperin | RS domain | Reduction of cholesterol and sphingomyelin at the plasma membrane; likely inhibition of virion budding through alteration of lipid rafts | 86 |
Vesicular stomatitis virus | Knockdown of viperin | ND | Unknown; proposed to be due to viperin-mediated promotion of RIG-I oxidation and stabilization | 69 | |
Orthomyxoviridae (−ssRNA group) | Influenza A virus | Overexpression of murine viperin in human cells; however, no effect observed in Viperin−/− mice | ND | Disruption of lipid rafts inhibits virus release from the plasma membrane | 70, 100 |
Arenaviridae (−ssRNA group) | Junín mammarenavirus | Overexpression of viperin and coimmunoprecipitations | N-terminal domain | Binds to viral N protein through its N-terminal domain at LDs and inhibits mRNA synthesis | 101 |
Peribunyaviridae (−ssRNA group) | Bunyamwera orthobunyavirus | Overexpression of viperin | RS domain (only domain tested) | Unknown | 102 |
Paramyxoviridae (−ssRNA group) | Respiratory syncytial virus | Overexpression of viperin in cell culture and in chinchillas, microscopy | ND | Unknown; may interfere with virus filament formation and cell-to-cell spread | 103, 104 |
Measles virus | Overexpression of viperin | N terminus, RS domain, C terminus | Inhibits virus release; no effects on titers of cell-associated virus | 85 | |
Retroviridae (ssRNA-RT group) | Human immunodeficiency virus-1 | Knockdown of viperin, overexpression of viperin, microscopy | RS domain; N-terminal and C-terminal domains are indispensable | Disruption of lipid rafts and inhibition of virion release from the plasma membrane; intact RS domain is required for redistribution of viperin to sites of virion release | 84 |
Abbreviations: CIA, cytosolic iron-sulfur protein assembly; co-IP, coimmunoprecipitation; ddhCTP, 3′-deoxy-3′, 4′-didehydro-cytidine triphosphate; dsDNA, double-stranded DNA; ER, endoplasmic reticulum; FRET, fluorescence resonance energy transfer; HCMV, human cytomegalovirus; JEV, Japanese encephalitis virus; KSHV, Kaposi’s sarcoma-associated herpesvirus; LD, lipid droplet; mRNA, messenger RNA; ND, not determined; NS3, nonstructural protein 3; NS5A, nonstructural protein 5A; nsP2, nonstructural protein 2; RdRp, RNA-dependent RNA polymerase; RIG-I, retinoic acid-inducible gene I; RS, radical S-adenosyl-L-methionine; RT, reverse transcriptase; SAM, S-adenosyl-L-methionine; ssRNA, single-stranded RNA; VAP-A, vesicle-associated membrane protein-associated protein-A; VLP, virus-like particle; vMIA, viral mitochondrial inhibitor of apoptosis.
Biochemical evidence indicates that neither the RS nor the C-terminal domain can operate independently, and their functions cannot be separated.